Hepatic CYP3A4, SULT2A1, and UGT1A1 synergistically mediate metabolic detoxification of genipin

doi:10.5246/jcps.2022.08.051

Abstract

Abstract:

In the present study, we aimed to ascertain the metabolic detoxification routes of genipin via CYP3A4, SULT2A1, and UGT1A1 in HepaRG cells. It was found that the hepatic CYP3A4, SULT2A1, and UGT1A1 synergistically mediated the metabolic detoxification of genipin, and the CYP3A4 was the limited enzyme. In detail, the pivotal detoxification pathway was CYP3A4-SULT2A1/UGT1A1, indicating that SULT2A1 and UGT1A1 further catalyzed the phase II detoxification metabolism followed by the genipin metabolization by CYP3A4 to the phase I metabolites with alleviated toxicity. Our findings provided valuable cues for future studies on the detoxification of genipin, even the compatibility detoxification of Zhi-zi. Moreover, these data facilitated the development and rational administration of genipin and Zhi-zi.

Key words: Genipin, Metabolic detoxification, CYP3A4, SULT2A1, UGT1A1, Gardenia jasminoides Ellis

Supporting:

Fan Zhang, Xiaohui Wang, Abdulaziz Ahmed A. Saad, Lili Xi, Xiaohua Ma, Axi Shi, Yuhui Wei. Hepatic CYP3A4, SULT2A1, and UGT1A1 synergistically mediate metabolic detoxification of genipin[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(8): 608-621.

Figures/Tables 7

References 31

[1]	Chen, L.P.; Li, M.X.; Yang, Z.Q.; Tao, W.D.; Wang, P.; Tian, X.Y.; Li, X.L.; Wang, W.G. Gardenia jasminoides Ellis: Ethnopharmacology, phytochemistry, and pharmacological and industrial applications of an important traditional Chinese medicine. J. Ethnopharmacol. 2020, 257, 112829.
[2]	Yang, Y.S.; Ding, Y.; Zhang, T. Biotransformation of geniposide into genipin by immobilized Trichoderma reesei and conformational study of genipin. Biomed. Res. Int. 2018, 2018, 2079195.
[3]	Xia, Z.S.; Hao, E.W.; Wei, Y.T.; Hou, X.T.; Chen, Z.M.; Wei, M.; Du, Z.C.; Deng, J.G. Genipin induces developmental toxicity through oxidative stress and apoptosis in zebrafish. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2021, 241, 108951.
[4]	Li, Y.W.; Li, L.; Hölscher, C. Therapeutic potential of genipin in central neurodegenerative diseases. CNS Drugs. 2016, 30, 889–897.
[5]	Shanmugam, M.K.; Shen, H.Y.; Tang, F.R.; Arfuso, F.; Rajesh, M.; Wang, L.Z.; Kumar, A.P.; Bian, J.S.; Goh, B.C.; Bishayee, A.; Sethi, G. Potential role of genipin in cancer therapy. Pharmacol. Res. 2018, 133, 195–200.
[6]	Fan, X.F.; Lin, L.; Cui, B.X.; Zhao, T.M.; Mao, L.H.; Song, Y.; Wang, X.Y.; Feng, H.J.; Yu, Q.X.; Zhang, J.; Jiang, K.; Cao, X.C.; Wang, B.M.; Sun, C. Therapeutic potential of genipin in various acute liver injury, fulminant hepatitis, NAFLD and other non-cancer liver diseases: more friend than foe. Pharmacol. Res. 2020, 159, 104945.
[7]	Guan, L.L.; Feng, H.Y.; Gong, D.Z.; Zhao, X.; Cai, L.; Wu, Q.; Yuan, B.; Yang, M.; Zhao, J.; Zou, Y. Genipin ameliorates age-related insulin resistance through inhibiting hepatic oxidative stress and mitochondrial dysfunction. Exp. Gerontol. 2013, 48, 1387–1394.
[8]	Guan, L.L.; Gong, D.Z.; Yang, S.R.; Shen, N.N.; Zhang, S.; Li, Y.C.; Wu, Q.; Yuan, B.; Sun, Y.P.; Dai, N.; Zhu, L.; Zou, Y. Genipin ameliorates diet-induced obesity via promoting lipid mobilization and browning of white adipose tissue in rats. Phytother. Res. 2018, 32, 723–732.
[9]	Wang, Z.; Liu, H.; Luo, W.; Cai, T.; Li, Z.; Liu, Y.; Gao, W.; Wan, Q.; Wang, X.; Wang, J.; Wang, Y.; Yang, X.. Regeneration of skeletal system with genipin crosslinked biomaterials. J. Tissue. Eng. 2020, 11, 2041731420974861.
[10]	Yu, Y.B.; Xu, S.; Li, S.M.; Pan, H. Genipin-cross-linked hydrogels based on biomaterials for drug delivery: a review. Biomater. Sci. 2021, 9, 1583–1597.
[11]	Muzzarelli, R.; El Mehtedi, M.; Bottegoni, C.; Aquili, A.; Gigante, A. Genipin-crosslinked chitosan gels and scaffolds for tissue engineering and regeneration of cartilage and bone. Mar. Drugs. 2015, 13, 7314–7338.
[12]	Manickam, B.; Sreedharan, R.; Elumalai, M. ‘genipin’–the natural water soluble cross-linking agent and its importance in the modified drug delivery systems: an overview. Curr. Drug Deliv. 2014, 11, 139–145.
[13]	Khanal, T.; Kim, H.G.; Choi, J.H.; Do, M.T.; Kong, M.J.; Kang, M.J.; Noh, K.; Yeo, H.K.; Ahn, Y.T.; Kang, W.; Kim, D.H.; Jeong, T.C.; Jeong, H.G. Biotransformation of geniposide by human intestinal microflora on cytotoxicity against HepG2 cells. Toxicol. Lett. 2012, 209, 246–254.
[14]	Hobbs, C.A.; Koyanagi, M.; Swartz, C.; Davis, J.; Maronpot, R.; Recio, L.; Hayashi, S.M. Genotoxicity evaluation of the naturally-derived food colorant, gardenia blue, and its precursor, genipin. Food Chem. Toxicol. 2018, 118, 695–708.
[15]	Cui, Y.Z.; Sun, R.; Wang, Q.J.; Wang, M.Z. Hepatotoxicity induced by intragastrically administrated with Gardenia Decoction in mice. Nat. Prod. Res. 2017, 31, 2824–2827.
[16]	Li, C.N.; Lan, M.; Lv, J.W.; Zhang, Y.; Gao, X.C.; Gao, X.; Dong, L.H.; Luo, G.M.; Zhang, H.; Sun, J.M. Screening of the hepatotoxic components in fructus gardeniae and their effects on rat liver BRL-3A cells. Molecules. 2019, 24, 3920.
[17]	Hou, Y.C.; Tsai, S.Y.; Lai, P.Y.; Chen, Y.S.; Chao, P.D.. Metabolism and pharmacokinetics of genipin and geniposide in rats. Food Chem. Toxicol. 2008, 46, 2764–2769.
[18]	Wang, G.W.; Bao, B.; Han, Z.Q.; Han, Q.Y.; Yang, X.L. Metabolic profile of Fructus Gardeniae in human plasma and urine using ultra high-performance liquid chromatography coupled with high-resolution LTQ-orbitrap mass spectrometry. Xenobiotica. 2016, 46, 901–912.
[19]	Chen, J.; Wu, H.; Dai, M.M.; Li, H.; Chen, J.Y.; Hu, S.L. Identification and distribution of four metabolites of geniposide in rats with adjuvant arthritis. Fitoterapia. 2014, 97, 111–121.
[20]	He, L.Q.; Zhou, X.H.; Huang, N.; Li, H.; Li, T.J.; Yao, K.; Tian, Y.N.; Hu, C.A.A.; Yin, Y.L. Functions of pregnane X receptor in self-detoxification. Amino Acids. 2017, 49, 1999–2007.
[21]	Zhou, S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 2008, 9, 310–322.
[22]	Al-Dujaili, E.A.S.; Kenyon, C.J.; Nicol, M.R.; Mason, J.I. Liquorice and glycyrrhetinic acid increase DHEA and deoxycorticosterone levels in vivo and in vitro by inhibiting adrenal SULT2A1 activity. Mol. Cell Endocrinol. 2011, 336, 102–109.
[23]	Tian, X.G.; Wang, C.; Dong, P.P.; An, Y.; Zhao, X.Y.; Jiang, W.R.; Wang, G.; Hou, J.; Feng, L.; Wang, Y.; Ge, G.B.; Huo, X.K.; Ning, J.; Ma, X.C. Arenobufagin is a novel isoform-specific probe for sensing human sulfotransferase 2A1. Acta Pharm. Sin. B. 2018, 8, 784–794.
[24]	Miners, J.O.; Chau, N.; Rowland, A.; Burns, K.; McKinnon, R.A.; Mackenzie, P.I.; Tucker, G.T.; Knights, K.M.; Kichenadasse, G. Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: implications for hyperbilirubinemia. Biochem. Pharmacol. 2017, 129, 85–95.
[25]	Li, D.Y.; Knox, B.; Chen, S.; Wu, L.H.; Tolleson, W.H.; Liu, Z.C.; Yu, D.K.; Guo, L.; Tong, W.D.; Ning, B.T. microRNAs hsa-miR-495-3p and hsa-miR-486-5p suppress basal and rifampicin-induced expression of human sulfotransferase 2A1 (SULT2A1) by facilitating mRNA degradation. Biochem. Pharmacol. 2019, 169, 113617.
[26]	Sugatani, J.; Uchida, T.; Kurosawa, M.; Yamaguchi, M.; Yamazaki, Y.; Ikari, A.; Miwa, M.S. Regulation of pregnane X receptor (PXR) function and UGT1A1 Gene expression by posttranslational modification of PXR protein. Drug Metab. Dispos. 2012, 40, 2031–2040.
[27]	Enoru-Eta, J.; Yengi, L.; He, X.Y.; Kubik, J.; Kao, J.; Scatina, J. Development of a UGT1A1 reporter gene assay for induction studies: correlation between reporter gene data and regulation of UGT1A1 in human hepatocytes. Drug Metab. Lett. 2010, 4, 31–38.
[28]	Han, H.; Yang, L.; Xu, Y.; Ding, Y.; Bligh, S.W.A.; Zhang, T.; Wang, Z.T. Identification of metabolites of geniposide in rat urine using ultra-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2011, 25, 3339–3350.
[29]	Ding, Y.; Hou, J.W.; Zhang, Y.; Zhang, L.Y.; Zhang, T.; Chen, Y.; Cai, Z.Z.; Yang, L. Metabolism of genipin in rat and identification of metabolites by using ultraperformance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Evid. Based Complement. Alternat. Med. 2013, 2013, 957030.
[30]	Almazroo, O.A.; Miah, M.K.; Venkataramanan, R. Drug metabolism in the liver. Clin. Liver Dis. 2017, 21, 1–20.
[31]	Jancova, P.; Anzenbacher, P.; Anzenbacherova, E. Phase II drug metabolizing enzymes. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czechoslov. 2010, 154, 103–116.